Immune-Related Adverse Events of Immune Checkpoint Inhibitors - FULL READ overview in Annals of Internal Medicine. irAEs occur from few days to 1 year after ICI initiation; w/ 3-fold higher risk 1st 4 wks & only 7% starting 1 year after ICI https://t.co/jxEAl3rlCd https://t.co/IlmvV5kNfP

ACR 2023 Poster Available on RheumNow: JAKi Safety and Efficacy Through Week 204 in bDMARD-IR Patients with RA View long-term extension outcomes from the SELECT-CHOICE study in bDMARD-IR patients with RA. Sponsored by AbbVie US Medical Affairs. https://t.co/3zEn9a2eml https://t.co/P7QXAmqJ2x

BC, Canada study of 149,902 new rheumatology referrals showed 31% more referrals 2019–2020 (vs 2010–2011). New inflammatory arthritis increased (28% to 51%), delays decr by 22 days; but time to 1st DMARD in RA decreased by only 4 days (6%) to 62 days https://t.co/LEyWcI6ojn https://t.co/QdL8VP1C6q

MMPs play pathogenic role in RA-ILD. Multicenter VA study of 2,312 RA pts, 96 had prevalent ILD & Incident ILD developed in 130 (IR 7.5/1,000PY). High MMP-7 increased ILD (adj OR 3.78) & incident ILD (adj HR 2.33). Higher MMP-9 did same https://t.co/W8IuDJCH8e https://t.co/UdiyyUt7jJ

UK Clinical Practice Research Datalink matched cohort study compared Gout (152K) to controls (709K) - CV devlopment higher in gout (21% vs 15%; HR 2.58). Moreso in women (HR 1.88). Gout pt had more CKD, HTN, obesity dyslipidaemia, & NIDDM https://t.co/BXCawnuIfa https://t.co/ZMuK9Msesb

2021 NHIS Survey data suggests the prevalence of immunosuppression in the USA is 6.6% (4.4% immunosuppressive Dz; 3.9% immunosuppressive meds; 1.8% both); higher in women 7.9% ages 60-69 (9.5%) & Alaskan/Native indian (8.4%) https://t.co/phFPRqpCbJ https://t.co/non7zpQVOL

FDA has issued new draft guidance on the "Use of Data Monitoring Committees in Clinical Trials", updating its 2006 guidance document. "..the DMC should have access to safety results as well as comparative efficacy results." https://t.co/F0vKOxCLq9 https://t.co/xBa4Q1ukqo https://t.co/KeBUsYIl6u

Serial plasma samples assayed for 92 inflammation-related proteins, during and after gout attacks. 21 were differentially expressed. Gout flares assoc w/ increased IL-6, CSF-1, VEGF-A & tumour necrosis factor superfamily 14 (TNFSF14 was highest) https://t.co/mhIFaljKHv https://t.co/o45Zzn0g9A

EMG fibrillation potentials (insertional activity) & positive sharp waves (Fib/PSW) are found in 95% study of 75 pts dx w/ idiopathic inflammatory myositis (44 PM, 17 DM, 7 ADM, 11 IBM); but also in 4 pts not meeting EULAR criteria https://t.co/VsrNjDMGnC https://t.co/OQYnUPJD5o

False positive COVID tests (+Rapid Ag; neg PCR) are rare, 1.7% of 11,297 tests; Persistent false positives seen in 13/191 and usually in women, with autoimmune dz (6/13; RA, SLE etc) & using the Quidel QuickVue rapid antigen test https://t.co/Pqkk7uBVcO https://t.co/m6ylQz00Ih

Join our experts, Drs Liebowitz and Mehta, as they provide insights on the differential diagnosis and management concepts in autoinflammatory diseases. https://t.co/r5WjYIdmaT https://t.co/gGdhyDKqtC

Week 52 outcomes of 180 lupus nephritis pts (IV, VI, III) from AMP academic centers (rx w/ standard of care) showed 22% complete resp,  22% partial resp, 42% non-responder& 14% undetermined. 8/180 (4.4%) had CR sustained Wk 12 to 52; 10% PR. An unmet need! https://t.co/UfYDKqHq1D https://t.co/zUIgvsZY6m